F2G’s olorofim gets FDA ODD for mold infections and Valley Fever

By on    Pharma Industry News  

F2G’s olorofim gets FDA ODD for mold infections and Valley Fever

F2G has bagged orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for olorofim (formerly F901318) for the treatments of invasive mold infections – invasive aspergillosis and lomentospora/scedosporium infections, and also the fungal infection – coccidioidomycosis (Valley Fever). For the three infections, there are significant unmet medical needs. In November 2019, F2G […]

F2G gets olorofim breakthrough therapy status from FDA for mold infections

By on    Pharma Industry News  

F2G gets olorofim breakthrough therapy status from FDA for mold infections

F2G has secured breakthrough therapy designation to olorofim (formerly F901318) from the US Food and Drug Administration (FDA)  for the treatment of certain invasive mold infections. The breakthrough therapy designation is for the use of olorofim in patients having limited or no treatment options, and also those who are intolerant to currently available therapy for […]